Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848481 · ClinicalTrials.gov registry record · Phase 2
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
A Phase 2 study of Prader-Willi Syndrome, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03848481 is a Phase 2 study of Prader-Willi Syndrome that has completed, run by Montefiore Medical Center. The registered enrollment target is 14 participants, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03848481, a Phase 2 study of Prader-Willi Syndrome, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CBDV Compound
Study Locations (1)
New York
- Montefiore Medical Center, Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03848481
The ClinicalTrials.gov registry entry for NCT03848481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (80% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03848481 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03848481 about?
NCT03848481 is a clinical study titled "CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)". This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.
What is the current status of trial NCT03848481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2020-11-23. Estimated completion is 2024-10-31.
What conditions does trial NCT03848481 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome.
What interventions are being tested in trial NCT03848481?
The interventions under investigation include: Placebo (DRUG), CBDV Compound (DRUG).
Who is sponsoring clinical trial NCT03848481?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03848481 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
COMPLETED · Phase 2
-
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
COMPLETED · Phase 2
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.